76. P. Lissoni, et al. "Five-year survival with high-dose melatonin and other antitumor pineal hormones in advanced cancer patients eligible for the only palliative therapy," *Research Journal of Oncology* (2018), vol. 2 no. 1: 2 (online) Mar. 26, 2018. Retrieved Apr. 29, 2021.
77. R. J. Reiter, et al. "Melatonin, a full-service anti-cancer agent: Inhibition of initiation, progression and metastasis." *International Journal of Molecular Sciences,* vol. 18,4 843. 17 Apr. 2017, doi:10.3390/ijms18040843.
78. Ibid.
79. B. Coiffard, et al. "A tangled threesome: Circadian rhythm, body temperature variations, and the immune system," *Biology,* vol. 10,1 65. 18 Jan. 2021, doi:10.3390/biology10010065.

CHAPTER 10

1. M. Orange, et al. "Coley's lessons remembered: Augmenting mistletoe therapy," *Integrative Cancer Therapies,* vol. 15,4 (2016): 502–11. doi:10.1177/1534735416649916.
2. L. K. Diamond and L. A. Luhby. "Pattern of 'spontaneous' remissions in leukemia of the childhood, observed in 26 of 300 cases," *Am. J. Med.,* 1951;10:238ff.
3. R. Kleef, et al. "Fever, cancer incidence and spontaneous remissions," *Neuroimmunomodulation* (2001) 9:55–64. doi: 10.1159/000049008.
4. M. Orange. "Mistletoe therapy for cancer patients. A thesis submitted to the University of Birmingham for the degree of Master of Science in Clinical Oncology," School of Cancer Sciences, University of Birmingham, 2010.
5. R. Steiner. *Physiology and Healing: Treatment, Therapy, and Hygiene* (CW 314), Op. cit., lecture of Oct. 27, 1922,
6. AUTHOR NOTE, DR. HANCOCK: For a little deeper examination of this matter, this webpage provides a calculator for calories burned while walking: https://caloriesburnedhq.com/calories-burned-walking/. This paper looks more closely at the toll fever takes on us: V. E. Baracos, et al. "The metabolic cost of fever," *Canadian Journal of Physiology and Pharmacology,* 65, no. 6 (June 1, 1987): 1248–54. https://doi.org/10.1139/y87-199. Here is the math: 1 kcal will raise 1 kg of water 1 degree Celsius. We are, on average 80kg, and mostly H2O. So, it takes roughly 80 kcal to raise body temperature 1 degree. We burn about 70 calories per mile (1.6 kilometers). We can estimate a 10 percent increase in basal metabolic rate (BMR) for every 1-degree Celsius increase. An average woman has a BMR of 1,400; an average man has a BMR of 1,800. Average that out, and you see about 1,600 kcal per degree, of which 10 percent is 160 kcal. This seems to be 2 miles or 3.2 km!
7. AUTHOR NOTE, DR. HANCOCK: The MFIT subcutaneous injection site will be large and palpable. Lymph nodes will still be activated. If necessary, one can do a PET in 2 weeks after MFIT and simply interpret the results in accordance with expected MFIT changes. As for IV, I usually allow a 2-week break between regular IV mistletoe and scans.

8. *Vademecum of Anthroposophic Medicines.* Association of Anthroposophic Medicine in Germany (GAAD); 2019.
9. AUTHOR NOTE, DR. HANCOCK: Although I've had a couple of patients who got significant fever with Helixor A, this was really an unintentional MFIT response.
10. R. Penter. "Der Injektionszeitpunkt und der Verlauf eines Zyklus der endogenen Hyperthermie bei der Mistelerstbehandlung" [The time of injection and the course of a cycle of endogenous hyperthermia in initial mistletoe treatment], *Der Merkurstab,* 2011(64):1.Jan.–Feb., 20–39.
11. M. Orange, et al. "Durable regression of primary cutaneous b-cell lymphoma following fever-inducing mistletoe treatment: Two case reports," *Phytomedicine,* 20, nos. 3–4 (Feb. 15, 2013), 324–27.
12. *Vademecum of Anthroposophic Medicines,* Association of Anthroposophic Medicine in Germany, 2019, chap. 7.
13. M. Orange. "Mistletoe therapy for cancer patients: A thesis submitted to the University of Birmingham for the degree of master of science in clinical oncology," School of Cancer Sciences, University of Birmingham, 2010.
14. M. T. Yilmaz, et al. "Abscopal effect, from myth to reality: From radiation oncologists' perspective," *Cureus,* vol. 11,1 e3860. Jan. 9, 2019, doi:10.7759/cureus.3860.
15. M. Zaric, et al. "Skin immunisation activates an innate lymphoid cell-monocyte axis regulating CD8+ effector recruitment to mucosal tissues," *Nat. Commun.,* 10, 2214 (2019). https://doi.org/10.1038/s41467-019-09969-2.
16. F. Schad, et al. "Intratumoral mistletoe (Viscum album L) therapy in patients with unresectable pancreas carcinoma: A retrospective analysis," *Integr. Cancer Ther.,* Jul. 2014;13(4):332-40. doi: 10.1177/1534735413513637. Epub 2013 Dec 19. PMID: 24363283.
17. *Vademecum of Anthroposophic Medicines.* Op. cit., chap. 7.
18. Jeong Su Cho, et al. "Chemical pleurodesis using mistletoe extraction (ABNOVAviscum® injection) for malignant pleural effusion," *Annals of Thoracic and Cardiovascular Surgery: Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia,* 22, no. 1 (2016): 20–26, https://doi.org/10/f8swjk.
19. YongJin Chang, et al. "Viscum pleurodesis is as effective as talc pleurodesis and tends to have less adverse effect," *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer,* 28, no. 11 (Nov. 2020): 5463–67, https://doi.org/10.1007/s00520-020-05405-0.
20. G. Bar-Sela, et al. "Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a viscum album extract," *Anticancer Research,* 26, no. 1B (Feb. 2006): 709–13.
21. R. Stange et al. "Favourable course of persisting malignant ascites," *Forschende Komplementarmedizin* (2006) 16, no. 1 (Feb. 2009): 49–53, https://doi.org/10/d7kwcv.
22. *Vademecum of Anthroposophic Medicines.* Op. cit., chap. 9.3, p. 144.

23. M. Girke, et al. "Ascites bei Non-Hodgkin-Lymphom (V.a. splenales Lymphom): Remission nach viermaliger intraperitonealer Viscumalbum-Instillation" [Ascites in non-Hodgkin lymphoma (V.a. splenal lymphoma): Remission after four intraperitoneal instillation of the viscum album], *Der Merkurstab: Zeitschrift für Anthroposophische Medizin*, 2012;65(3):257-258. DOI: https://doi.org/10.14271/DMS-19967-de.
24. R. Achim, et al. "Mistletoe plant extract in patients with nonmuscle invasive bladder cancer: Results of a phase Ib/IIa single group dose escalation study," *The Journal of Urology*, 194, no. 4 (Oct. 2015): 939–43 (https://doi.org/10.1016/j.juro.2015.04.073).
25. H. Rexer and Geschäftsstelle der AUO, "Study on the treatment of non-muscle invasive bladder cancer: A phase-III efficacy study for intravesical instillation of mistletoe extract in superficial bladder cancer (TIM) AB 40/11 of the AUO," *Der Urologe. Ausg.*, A 54, no. 3 (Mar. 2015): 406–08, https://doi.org/10.1007/s00120-015-3781-8.
26. Vademecum of Anthroposophic Medicines. Published by Association of Anthroposophic Medicine in Germany (GAAD); 2019, chap. 7.9.
27. M. Debus. "Anwendungsmöglichkeiten von Helleborus niger in der Onkologie" [Possible uses of Helleborus in oncology.] *Der Merkurstab: Zeitschrift für Anthroposophische Medizin*, 2010;63(6):551–557.
28. K. M. Brintzenhofe-Szoc, et al. "Mixed anxiety/depression symptoms in a large cancer cohort: Prevalence by cancer type," *Psychosomatics*, 2009 Jul.–Aug. 50 (4):383–91.
29. S. Mayr, RM. "Depression in pancreatic cancer: Sense of impending doom," *Digestion*, 2010;82:1–3.
30. D. K. Andersen, et al. "Diabetes, pancreatogenic diabetes, and pancreatic cancer," *Diabetes*, May 2017, 66 (5) 1103–10. doi: 10.2337/db16-1477.
31. A. Marengo, et al. "Liver cancer: Connections with obesity, fatty liver, and cirrhosis," *Annual Review of Medicine*, vol. 67 (2016): 103–17. doi:10.1146/annurev-med-090514-013832.
32. G. J. Koelwyn, et al. "Exercise-dependent regulation of the tumour microenvironment," *Nat. Rev. Cancer*, 2017 Sep. 25;17(10):620-632. doi: 10.1038/nrc.2017.78. PMID: 28943640.
33. S. O. Dalton, et al. "Mind and cancer: Do psychological factors cause cancer?" *Eur. J. Cancer*, 2002JUI;38 (10):1313-23.
34. M. A. Nordstrom, et al. "Sick leave due to depressive disease: Not a risk factor for the development of malignant lymphoma," *Eur. J. Epidemiol.*, 2005;20 (9): 769–73.
35. J. R. Cerhan, et al. "Anthropometric characteristics, physical activity, and risk of non-Hodgkins lymphoma subtypes and B-cell chronic lymphocytic leukemia: A prospective study," *Am. J. Epidemiol.*, Sep. 15, 2002; 156 (6): 527–35.
36. L. Jachens. "Das maligne Melanom ausanthroposophisch-menschenkundlicher Sich" [The malignant melanoma from the anthroposophic point of view], *Der Merkurstab*, 2005(58):5 Sep.–Oct.; 375–89.
37. AUTHOR NOTE: Full ACS statement reads, "Breast cancer is the most common cancer in American women, except for skin cancers" (according to American Cancer Society statistics, at: https://www.cancer.org/cancer

/breast-cancer/about/how-common-is-breast-cancer.html. Accessed Apr. 22, 2021).

38. American Cancer Society. *Cancer Facts and Figures 2020,* Atlanta, GA: American Cancer Society, 2020.
39. "Blood Cancers," National Foundation for Cancer Research; monograph at: https://www.nfcr.org/cancer-types/blood-cancer. Accessed Apr. 22, 2021.
40. N. Becker, et al. "Self-reported history of infections and the risk of non-Hodgkin lymphoma: An interlymph pooled analysis," Intl. *Journal of Cancer. Journal Intl. Du Cancer,* 131 no 10; Nov 15, 2012: 2342–48.
41. S. Parodi, et al. "Childhood infectious diseases and risk of non-Hodgkin's lymphoma according to the WHO classification: A reanalysis of the Italian multicenter case-control study," *Int. J. Cancer,* 2020 Feb 15;146(4):977-986. doi: 10.1002/ijc.32393. Epub 2019 May 17. PMID: 31077355.
42. H. F. Fischer, et al. "The effect of attending Steiner schools during childhood on health in adulthood: A multicentre cross-sectional study," *PLoS ONE,* 8, no. 9 (Sept. 12, 2013); https://doi.org/10.1371/journal.pone.0073135.
43. M. Girke, *Internal Medicine,* Op. cit.
44. A. C. Xavier, et al. "Down syndrome and malignancies: A unique clinical relationship," *Journal of Molecular Diagnostics: JMD,* 11, no. 5; 2009: 371–80.
45. J. Grieco, et al. "Down syndrome: Cognitive and behavioral functioning across the lifespan," *American Journal of Med. Genetics, Part C: Sems. in Med. Genetics,* 169. No 2. 2015: 135-49.
46. *Vademecum of Anthroposophic Medicines*, Association of Anthroposophic Medicine in Germany, 2019, chap. 9.
47. C. Stumpf, et al. "Therapie mit Mistelextrakten bei malignen ha¨matologischen und lymphatischen Erkrankungen" [Mistletoe extract therapy for malignant haematological and lymphatic diseases], *Eine monozentrische retrospektive Analyse u¨ber 16 Jahre: Forschende Komplementa¨rmedizin,* 2000; 7(3): 139–46.
48. J. J. Kuehn. "Langfristig guter Verlauf unter Misteltherapie bei einem Patienten mit einem zentrozytisch-zentroblastischen non-Hodgkin-lymphom" [Long-term good progress with mistletoe therapy in a patient with centrocytic-centroblastic non-Hodgkins lymphoma], *Deutsche Medizinische Wochenschrift,* 1999; 124(47): 1414–18. http://doi.org/10.1055/s-2007-1024555.
49. G. Seifert, et al. "Response to subcutaneous therapy with mistletoe in recurrent multisystem Langerhans cell histiocytosis," *Pediatric Blood and Cancer,* 2005; 48(5): 591–92 (http://doi.org/10.1002/pbc.20649).
50. This section, written by Debus, originally appeared in *Vademecum of Anthroposophic Medicines,* Op. cit., chap. 9.1.
51. M. Girke. *Internal Medicine,* Op. cit., chap. 9.
53. *Vademecum of Anthroposophic Medicines,* Op. cit., chap. 9, case description 142–143.

54. M. Orange, et al. "Durable regression of primary cutaneous b-cell lymphoma following fever-inducing mistletoe treatment: Two case reports," *Phytomedicine,* 20, nos. 3–4 (Feb. 15, 2013): 324–27.
55. T. Srdic-Rajic, et al. "Sensitization of K562 leukemia cells to Doxorubicin by the VAE: Viscum album enhances Doxorubicin antitumor effects," *Phytotherapy Research,* 30 no 3 2016: 483–95.
56. C. I. Delebinski, et al. "A natural comb. ext. of VA L. containing both triterpene acids and lectins is highly effective against AML in Vivo," *PloS One,* no. 8, 2015: e0133892.
57. M. P. Rausch and K. T. Hastings. "Immune checkpoint inhibitors in the treatment of melanoma: From basic science to clinical application," *Cutaneous Melanoma: Etiology and Therapy* (chap. 9), W. H. Ward, J. M. Farma (eds.); Brisbane (AU): Codon Publications, 2017 Dec 21.
58. G. Lahat, et al. "Sarcoma epidemiology and etiology: Potential enviro and genetic factors," *Surgical Clinics of North Am.,* 88, no 3; 2008: 451–81.
59. AUTHOR NOTE: Lymphoma and leukemia actually have two peaks: in youth and in older age. When such cancers appear in older age, we view the restraining/structuring forces as weakening.
60. R. Leroi. "Das Sarkom und seine Therapie, Teil I: Über die Bildung der Sarkome" [Sarcoma and its therapy, part I: On the formation of the sarcoma], *Beiträge zu einer Erweiterung der Heilkunst nach geisteswissenschaftlichen Erkenntnissen,* 1970;23(2):45–51. DOI: https://doi.org/10.14271/DMS-12805-DE.
61. Ibid., part 2: For Sarcoma Therapies.
62. R. D. Issels, et al. "Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma," *JAMA Oncology,* 4, no 4; 2018. 483-92.
63. A. Kirsch and T. Hajto. "Case reports of sarcoma patients with optimized lectin-oriented mistletoe extract therapy," *Journal of Alt. and Comp. Med.,* 17, 10; 2011: 973–79.
64. T. Waschakidze. "Intraläsionale Misteltherapie bei einer Patientin mit Liposarkom–eine Fallvignette aus Georgien" [Intralesional mistletoe therapy in a patient with liposarcoma–a case vignette from Georgia], *Der Merkurstab,* 69, no. 3 (2016): 205–7, https://doi.org/10.14271/DMS-20638-DE.
65. A. Longhi, et al. "Long-term follow-up of a randomized study of oral etoposide versus viscum album fermentatum pini as maintenance therapy in osteosarcoma patients in complete surgical remission after second relapse," *Sarcoma,* 2020;2020:8260730. Apr. 26, 2020. doi:10.1155/2020/8260730.
66. M. Reynel, et al. "Long-term survival of a patient with recurrent dedifferentiated high-grade liposarcoma of the retroperitoneum under adjuvant treatment with viscum album l. extract: A case report," *Integral Cancer Ther.,* 2021 Jan.–Dec.;20:1534735421995258. doi: 10.1177/1534735421995258. PMID: 33618582; PMCID: PMC7905720.
67. A. Orton, et al. "A case of complete abscopal response in high-grade pleiomorphic sarcoma treated with radiotherapy alone," *Cureus,* vol. 8,10 e821. Oct. 7, 2016, doi:10.7759/cureus.821.

68. R. J. Brenneman, et al. "Abscopal effect following proton beam radiotherapy in a patient with inoperable metastatic retroperitoneal sarcoma," *Front Oncol.*, 2019 Sep 26;9:922. doi: 10.3389/fonc.2019.00922. PMID: 31616634; PMCID: PMC6775241. https://pubmed.ncbi.nlm.nih.gov/31616634.
69. E. Pennacchioli, et al. "Hyperthermia as an adjunctive treatment for soft-tissue sarcoma," *Expert Review of Anticancer Therapy,* vol. 9,2 (2009): 199-210. doi:10.1586/14737140.9.2.199.
70. R. D. Issels, et al. "Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: The EORTC 62961-ESHO 95 randomized clinical trial," *JAMA Oncology,* vol. 4,4 (2018): 483-492.
71. *Cancer Facts and Figures 2020,* Atlanta: American Cancer Society, 2020.
72. Q. T. Ostrom, et al. "Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014," *JAMA Oncology.* 4, 9, 2018.
73. Q. T. Ostrom, et al. "The epidemiology of glioma in adults: A 'state of the science' review," *Neuro-oncology,* 16, 7; 2014: 896–913.
74. AUTHOR NOTE: By this definition nerve cells are undergoing tiny death-like states on a continuous basis (this also links to consciousness). Dr. Armin Husemann discusses this in some of his books. This principle has fascinating connections to the threefold human.
75. J. de Weille. "On the genesis of neuroblastoma and glioma," *International Journal of Brain Science,* vol. 2014, Article ID 217503, 14 pages.
76. "Glial cells–development and stem cells" *Embryonic Development and Stem Cell Compendium, LifeMap Discovery;* monograph at https://discovery.lifemapsc.com/in-vivo-development/glial-cells. Accessed Apr. 23, 2021.
77. S. Jakel and L. Dimou. "Glial cells and their function in the adult brain: A journey through the history of their ablation," *Frontiers in Cellular Neuroscience,* 11: 2017.
78. I. S. Muskens, et al. "Germline genetic landscape of pediatric central nervous system tumors," *Neuro-oncology,* vol. 21,11 (2019): 1376–88. doi:10.1093/neuonc/noz108.
79. T. Bouzek. "Misteltherapie bei Patienten mit Hirntumoren: 3 Kasuistiken" [Mistletoe therapy in patients with brain tumors: 3 case reports], *Der Merkurstab* 2012;65(3):249-256. Article-ID: DMS-19966-DE. DOI: https://doi.org/10.14271/DMS-19966-DE.
80. N. Mckinney. *Naturopathic Oncology: An Encyclopedic Guide for Patients and Physicians* (4th ed.), Victoria, Canada: Liaison, 2020.
81. K. L. Pitter, et al. "Corticosteroids compromise survival in glioblastoma," *Brain,* 139, 5; 2016: 1458-71.
82. A. Poff, et al. "Targeting the Warburg effect for cancer treatment: Ketogenic diets for the management of glioma," *Seminars in Cancer Biology,* 56 June 2019.
83. T. N. Seyfried, et al. "Role of glucose and ketone bodies in the metabolic control of experimental brain cancer," *British Journal of Cancer,* 2003.